Suraksha Diagnostic Limited has informed the Exchange about Investor Presentation
Date: 29 May 2025
To
The Secretary BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001 Scrip Code: 544293
Dear Sir / Ma’am,
The Secretary The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1. G Block
Bandra -Kurla Complex, Bandra (East)
Mumbai- 400 051 Scrip Symbol : SURAKSHA
Reg: Disclosure under Regulation 30(6) of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015
Sub: Presentation to be made at the Analyst(s) / Investor(s) Meet/ Conference- Earnings Call
Pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and further to our intimation dated 24 May 2025 regarding schedule of Analyst(s)/ Investor(s) Meet /Conference i.e Earnings Call on Friday, 30 May 2025 at 03:00 pm (IST), we are hereby enclosing a copy of Investor Presentation on the audited (standalone and consolidated) financial results of the Company for quarter and financial year ended 31 March 2025.
The Investor Presentation will be exhibited at the aforesaid Earnings Call and the same is available on the website of the Company at https://www.surakshanet.com/pdf/investor/Suraksha-Investor- Presentation-Q4%20-FY-2024-25.pdf.
Please note that the schedule of the aforesaid Earnings Call is subject to change. The changes might happen due to exigencies on the part of the Company/ Analyst(s)/ Investor(s).
This may please be informed to all the concerned.
For Suraksha Diagnostic Limited
_________________ Mamta Jain Company Secretary & Compliance Officer
Encl: As above
Suraksha Diagnostic Limited CIN: L85110WB2005PLC102265 Reg Office: 12/1, Premises No. 02-0327, DG Block, Action Area 1D, New
Town, Kolkata-700 156, West Bengal, India
E-mail: investors@surakshanet.com I Website: www.surakshanet.com Phone:(033) 6605 9750
Suraksha Diagnostic Limited Q4 & FY25 Investor Presentation
Safe Harbor Statement
This presentation and the accompanying slides (the “Presentation”), which have been prepared by Suraksha Diagnostic Limited (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.
This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.
Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.
All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.
2
Q4 & FY25 Highlights
3
Consolidated Financial Performance – FY25
Total Income (₹ million)
EBITDA (₹ million)
PAT (₹ million)
33.7%
33.8%
10.6%
12.3%
+15%
2,559
2,223
+16%
851
736
+34%
310
231
FY24
FY25
FY24
FY25
FY24
FY25
4
Consolidated Financial Performance – Q4 FY25
Total Income (₹ million)
EBITDA (₹ million)
PAT (₹ million)
37.1%
31.7%
30.7%
11.5%
10.1%
11.0%
+17%
601
562
659
204
-2%
189
200
+13%
60
63
72
Q4FY24
Q3FY25
Q4FY25
Q4FY24
Q3FY25
Q4FY25
Q4FY24
Q3FY25
Q4FY25
5
Consistent Performance Over the Years
ROE %
ROCE %
Number of Tests (million)
14.09
16.29
21.46
23.30
5.98
6.69
5.17
4.32
9.05
FY23
FY24
FY25
FY23
FY24
FY25
FY23
FY24
FY25
Number of Centres
Revenue / Patient (₹)
EBITDA / Patient(₹)
43
48
55
1712
+24%
1922
2118
67%
647
715
427
FY23
FY24
FY25
FY23
FY24
FY25
FY23
FY24
FY25
6
Expanding Offerings Through Strategic Acquisition
Key Highlights of Strategic Investment
ABOUT FETOMAT
•
•
•
•
Incorporated in May 2021, Fetomat Wellness Private Limited (“Fetomat”) is a network of fertility and pregnancy care clinics
Fetomat specializes in pregnancy care, women’s ultrasound scans, prenatal diagnosis and advanced therapies
Fetomat is one of Eastern India’s leading centers for fetal and maternal medicine and operated 2 centers as of 31 March, 2024
For FY24, Fetomat’s turnover was ₹ 4.11 crore with an EBITDA of ₹ 0.56 crore
In March 2025, the Board approved a proposal for a strategic investment in Fetomat
Upon deal completion in April 2025, we held 63% stake in Fetomat
This strategic acquisition will help integrate fetal medicine expertise into our existing healthcare framework
The synergies with Fetomat will enhance innovation in fetal medical diagnostics, strengthening our industry position
Suraksha Diagnostic Limited| Investor Presentation
7
Profit & Loss Statement (Consolidated)
Particulars (₹ million)
Q4 FY25
Q4 FY24
Y-o-Y
Q3 FY25
Q-o-Q
Revenue from Operations
Other Income
Total Revenue
Cost of Material Consumed
Employee Benefit Expenses
Other Expenses
Impairement Loss
EBITDA
EBITDA Margin (%)
Depreciation
Finance Cost
Profit before Tax & Exceptional Item
Exceptional Item
Profit before Tax
Profit before Tax (%)
Tax
Profit After Tax
PAT Margin (%)
EPS
650.95
8.17
659.12
88.48
102.03
260.53
8.02
200.05
30.7%
87.29
20.63
92.13
0.00
92.13
14.2%
20.42
71.71
11.0%
1.42
551.88
9.79
561.67
65.77
89.97
199.46
2.00
204.48
37.1%
83.59
20.78
100.11
7.79
92.32
18.1%
29.11
63.21
11.5%
1.22
17.35%
-2.17%
-7.98%
-0.22%
13.44%
595.13
5.99
601.12
61.03
112.87
229.85
8.82
188.55
31.7%
88.27
19.82
80.47
0.00
80.47
13.5%
20.62
59.85
10.1%
1.18
9.65%
6.09%
14.49%
14.49%
19.82%
FY25
2520.93
38.46
2559.39
295.19
428.90
962.55
21.86
850.88
33.8%
352.98
83.85
414.05
0.00
414.05
16.4%
104.27
309.78
12.3%
5.97
FY24
2187.09
35.51
2222.59
272.51
400.68
811.88
1.34
736.18
33.7%
325.98
87.88
322.31
7.79
314.53
14.7%
83.26
231.26
10.6%
4.43
Y-o-Y
15.15%
15.58%
28.46%
31.64%
33.95%
8
Balance Sheet (Consolidated)
Particulars (₹ million)
FY25
FY24
Particulars (₹ million)
Property, plant and equipment
1,471.37
1,350.50
Capital work-in-progress
Right-of-use assets
Other intangible assets
Intangible Assets under Development
Financial assets
Investments
Other financial assets
Non-current tax assets (net)
Other non-current assets
Total non-current assets
Inventories
Financial assets
Trade receivables
Cash and cash equivalents
100.99
742.90
15.00
4.93
10.00
426.91
16.28
75.33
13.13
754.09
10.76
84.49
18.31
46.27
2,863.71
2,277.56
80.49
66.78
138.12
22.47
88.75
25.20
Bank balances other than cash and cash equivalents
178.59
525.03
Other financial assets
Other current assets
Total current assets
Total Assets
Suraksha Diagnostic Limited| Investor Presentation
25.30
26.56
471.53
-
18.73
724.49
3,335.24
3,002.05
Equity share capital Instruments entirely equity in nature Other equity
Equity attributable to owners of the parent Non Controlling interest
Total equity
Financial liabilities
Borrowings Lease liabilities
Provisions Deferred tax liabilities (net)
Total non-current liabilities
Financial liabilities
Borrowings Lease liabilities Trade payables
-
FY25
104.16
2,008.24
2,112.40 (10.09) 2,102.31
28.75 712.28 10.22 54.51 805.76
29.50 118.38
FY24
69.00 16.29 1,708.80
1,794.08 -2.62 1,791.46
51.83 703.07 7.71 53.86 816.47
34.54 115.33
Total outstanding dues of micro enterprises and small enterprises Total outstanding dues other than above micro enterprises and small enterprises
19.67
32.26
116.76
111.66
Other financial liabilities
Other current liabilities Provisions Current tax liabilities (net)
Total current liabilities Total equity and liabilities
107.72 33.80 1.25 0.08 427.17 3,335.24
77.68 17.46 - 5.19 394.12 3,002.05
9
Cash Flow Statement (Consolidated)
Particulars (₹ million)
FY25
FY24
Particulars (₹ million)
Cash flow from operating activities Profit before tax Adjustments for: Depreciation and amortisation expenses Finance costs Interest on loans, deposits and IT refund Unwinding of security deposit Exceptional items Loss on sale of property, plant and equipment Provision for credit allowances on receivables and deposits Security deposits written off Bad debts written off Share based payment expenses Liabilities/ provisions no longer required written back Operating profit before working capital changes Changes in operating assets and liabilities Adjustments for (increase) / decrease in operating assets Trade receivables Inventories Other financial assets Other assets Adjustments for increase / (decrease) in operating liabilities Trade payables Other non-current liabilities Other liabilities
Suraksha Diagnostic Limited| Investor Presentation
414.05
314.52
352.98 83.85 -32.45 -3.34 0.00 2.56 21.86 0.67 2.68 2.11 -2.30 842.67
-72.12 -13.71 -30.94 -7.82
-5.19 0.00 16.34
325.98 87.88 -32.20 -2.97 7.79 21.45 1.342 - 4.02 - - 727.82
-47.31 -5.16 5.29 2.97
3.54 0 5.06
Other financial liabilities Provisions Cash generated from operations Income tax paid (net) Net cash flows generated from operating activities Cash flows from investing activities Purchase of property, plant & equipment, other intangible assets and intangible asset under development (including capital work-in-progress, capital advances and capital creditors) Proceeds from sale of property, plant & equipment Net Redemption/(Investments) in deposits with banks Investment in Company Interest received on bank deposits Net cash flows used in investing activities Cash flow from financing activities Contribution from non-controlling interests Proceeds of borrowings Repayment of borrowings Payment of lease liabilities Finance cost paid Net cash flows used in financing activities Net increase in cash and cash equivalents Cash and cash equivalents at the beginning of the year Cash and cash equivalents at the end of the year
FY25
9.15 1.04 739.41 -105.82 633.59
FY24
-1.77 0.50 690.92 -86.10 604.81
-420.24
-454.72
1.41 -2.60 -10.00 35.59 -395.84
1.00 0.00 -28.11 -207.00 -6.37 -240.48 -2.73 25.20 22.47
25.52 47.36 0 31.90 -349.95
7.03 5 -58.69 -195.55 -9.08 -251.29 3.57 21.6 25.2
10
KPIs for FY25
Particulars
Units
FY25
Particulars
Units
FY25
Particulars
Units
FY25
Number of tests per patient^
Unit
Number of tests performed
Unit in million
6.69
Revenue from operations
5.52
100
93.12
6.88
45.22
50.81
3.97
55
9
4
1.19
Revenue generated from East India
B2C revenues
B2B revenues
Revenue from radiology
Revenue from pathology
Revenue from Doctor Consultancy
Number of Centres
Number of Laboratories
Number of NABL accredited labs
Number of patients served
Number of patients served per centre
%
%
%
%
%
%
Unit
Unit
Unit
Unit in million
Suraksha Diagnostic Limited| Investor Presentation
Number of Small centres
Number of Medium centres
Number of Large centres
Number of Private public partnerships
Customer touch points
• Number of Centres
• Collection Centres
• Company Owned Collection
Centres
Total Touch points
Number of doctors (Radiologist & Pathologist)
Number of CT machines
Unit
Unit
Unit
Unit
Unit
Unit
Unit
Unit
Unit
Unit
Unit
26
11
14
4
55
171
4
230
313
26
14
Unit
23,333
Number of MRI machines
Restated profit for the year
EBITDA
EBITDA Margin
Return on Equity
Return on Capital Employed
Net debt/equity
(₹ in million)
(₹ in million)
(₹ in million)
%
%
%
-
2,520.93
309.78
850.88
33.75
16.29
23.30
0.33
Average revenue per patient
(₹)
2,118
Average revenue per centre
EBITDA per patient
Return on Net Worth
Net asset value per Equity Share (Basic & Diluted)
(₹ in million)
(₹)
%
(₹)
45.84
715
16.29
40.56
11
Company Overview
12
Business at a Glance
as of 31 March, 2025
9
Labs
55
Diagnostic Centres
171
1.19 million
6.69 million
₹ 2,118
Patients Served (FY25)
Tests Performed (FY25)
Revenue per patient (FY25)
313
Doctors
4
26
CT Machines
₹ 715
EBITDA per patient (FY25)
14
₹ 280 million
Collection Centres
NABL accredited labs
MRI Machines
Note: National Accreditation Board for Testing and Calibration Laboratories (NABL)
Revenue per lab (FY25)
13
Evolution to the Largest Integrated Diagnostic Chain in East India
1992
Built fully comprehensive diagnostic centre, under brand ‘Suraksha’
2010
5 centres
2007
2013
2016
Received second round of funding from OrbiMed
Exit of Lighthouse Funds
25 centres
4 Labs
2024
53 centres
9 Labs
2020
IPO and listing on BSE and NSE
Launched the first centre of the Company
1 centre
Received first round of funding from PE investor Lighthouse Funds
Acquisition of 2 pre- existing diagnostic centres in Kolkata from Future Medical & Research Trust
14
Deeply Entrenched in the Vital Geography of West Bengal
2
2
52 Centers in West Bengal
•
•
•
4th most populous state in India Fragmented market with low penetration of chained diagnostic centers Accounted for 95.5% of FY24 Revenue from operations
Bihar
Assam
West Bengal
Meghalaya
1
No. of centres
>10 centres
3 centres
2 centres
1 centres
Population Legend
No. of people >8.5 mn
6.0 – 8.5 mn
4.0 – 6.0 mn
2.0 – 4.0 mn
<2.0 mn
15
1
2
1
Helabattala
3
Bardhaman
21
SRPL-Garden Reach
2
Shyamnagar
1
2
11
1
2
Hub & Spoke Operating Model
Modalities Offered
Key Stats
s e r t n e C b u H
s e r t n e C e k o p S
Large
Centres
Medium Centres
Small Centres
Note: 1) as of 31 March 2025
MRI
CT Scan
USG
Gastroenterology Neurology
Pathology
X-Ray
Cardiology
Mammo
OPG
Dexa
CT-Scan
USG
X-Ray
Neurology
Cardiology
Pathology
USG
X-Ray
Cardiology
Pathology
# of doctors & employees / centre
Area
30-40
5,000 – 8,000 sq. ft
20-25
2,500 – 5,000 sq. ft
12-15
1,500 – 3,500 sq. ft
16
Demonstrated success in Kolkata region with significant potential for future growth2
…..with Demonstrated Success
Operational Network(1)
1 Central Lab
8 Satellite Labs
14 Hub Centres
(co-located with hub centres)
(equipped to conduct all pathology sample collection, basic and advanced radiology tests)
11 Medium Centres
26 Small Centres
4 PPP
171 Sample Collection Centres
Spoke Centres
(equipped to conduct all pathology sample collection and certain basic & intermediate radiology tests)
Enhanced brand penetration through ability to serve more customers
Unlocks economies of scale
Hub centres Offers pathology tests, basic & advanced radiology tests
Spoke centres Offers pathology tests, basic and intermediate radiology tests
Note: 1) as of 31 March 2025; 2) Map illustrating the ‘hub and spoke’ model in the diagnostic centre network in Greater Kolkata, representing clusters formed by combining the hub centres and spoke centres
17
Well-established Operational Network - Greater Economies of Scale
Report Flow
Patient
Image/Report Flow
Image Flow
Patients Flow
Doctor
Polyclinic Doctor
Hospital
Customers
Samples
Sample Flow
Patient Flow
Suraksha Diagnostic Limited| Investor Presentation
P.A.C.S (Software)
RAD (Scrutiny)
IMAGE (Report)
#14
Hub Centre
#39
Spoke Centre
Collection Centre #187
Home Collection
#1 Flagship Reference Lab
#8
SATELLITE LAB
18
Well Equipped Clinical Infrastructure
Suraksha Diagnostic Limited| Investor Presentation
19
Customer Convenience through Value Added Services
Customer Centric Approach
Value Added Services enhancing customer experience and convenience
Home Collection
SMS Alerts
Polyclinic Chambers
Online Bookings
Allows samples to be collected from the consumers’ locations, such as their homes or offices
Customers receive an SMS to download the report through email or web portal
Polyclinic chambers hosting doctors providing out-patient consultation
Customers can book appointments and access test reports online
Supported by IT Infrastructure
LIMS
RIS
PACS
ERP
Laboratory Information Management System
Fully integrated Radiology Information Systems
Picture Archive and Communication Systems
Enterprise Resource Planning
Streamline operations
Reduce margin of error
Maintain the TAT
Customer convenience
20
More convenience through online test bookings, consultations and digital test results
Experienced Board of Directors
Dr. Somnath Chatterjee Chairman & Joint Managing Director
o Associated with Suraksha since incorporation; 32+ years of experience in
medical and diagnostics business
o Holds bachelor’s degree in medicine and surgery from University of Calcutta
and is registered with West Bengal Medical Council
Mr. Satish Kumar Verma Non-Executive, Non-Independent Director
o 40+ years of experience in management o Holds a bachelor’s degree in mechanical engineering and post-graduate diploma
in engineering from Punjab University
Mr. Pradip Kumar Dutta Independent Director
o Several years of work experience. Currently, an advisor to board at Simyog
Technology
o Holds B.Tech degree in electronics & electrical communication engineering from IIT, Kharagpur; a MS degree and doctorate in philosophy from the University of Maryland
Ritu Mittal Joint Managing Director & Chief Executive Officer
o Associated with Suraksha since incorporation; 28+ years of experience in
the medical and diagnostics business
o Cleared the examination for a bachelor’s degree in commerce from the
University of Calcutta
Mr. Arun Sadhanandham Non-Executive, Non-Independent (Nominee) Director
o Nominee of OrbiMed Asia II Mauritius Limited; 13+ years of work
experience
o Holds bachelor’s degree of engineering from Anna University, Chennai and
post graduate diploma in management from IIM, Bengaluru
Mr. Siddhartha Roy Independent Director
o 39+ years of experience o Holds bachelor’s degree in law from Calcutta University, and also a
member of the Institute of Company Secretaries of India
Ms. Ishani Ray Independent Director
Mr. Dharam Chand Dharewa Independent Director
o 27+ years of experience in finance o Holds bachelor’s degree and master’s degree in commerce from the University of Calcutta; she is an associate of the Institute of Chartered Accountants of India
o 30+ years of experience o Holds bachelor’s degree in commerce from G.D. Binani Mahavidyalaya,
and is practicing chartered accountant since 1987
21
Dynamic and Diverse Management Team to Deliver the Next Phase of Growth
Ravindra K S Group Chief Financial Officer
Professional with over 20 years of extensive experience in the finance sector including the role of Group CFO at Medica Hospitals Group, Group Finance Controller at Narayana Hrudayalaya Limited and Group Manager-Finance at Aditya Birla Nuvo Limited
He has a Bachelor’s in Commerce from Kuvempu University and is a member of the Institute of Chartered Accountants of India
Balgopal Jhunjhunwala Regional Business Head
15+ years of experience
Holds bachelor’s degree in commerce from University of Calcutta
Sangeeta Chakraborty General Manager, Operations
26+ years of experience
She holds a Bachelor's degree in Arts from the University of Calcutta. She previously worked in the healthcare industry, managing inventory operations and contributing to process efficiency and supply chain coordination
Mamta Jain Company Secretary & Compliance Officer
9+ years of experience including with VISA International Limited and Dollar Industries Limited. Holds bachelor’s degree in commerce from University of Calcutta, associate member of ICSI , member of the ICWAI and diploma in business administration from Symbiosis Centre for Distance Learning
Niren Kaul Chief Sales Officer
22+ years of experience, including with Bharti Hexacom Limited and Bharti Infratel Limited. Holds bachelor’s degree in electrical engineering from Pandit Ravishankar Shukla University, Raipur and master’s degree in business administration from University of Pune
Ajeet Kumar Yadav GM Supply Chain Management
20+ years of experience included with Aster DM Healthcare Holds bachelor’s degree in commerce from University of Calcutta and PG in Business Management from ICFAI University Tripura and pursuing Master’s degree in in Production and Operation Management from Amity University for Distance Learning
22
Strategy and Outlook
23
Leveraging Strengths to Drive Competitive Advantage
01
02
03
04
Largest diagnostic chain with a dominant position in Eastern India; well-positioned to benefit from the high-growth opportunity for organized diagnostic chains in the fragmented markets in Eastern and North- Eastern India
Integrated diagnostics provider with one-stop solution offering pathology & radiology testing, and medical consultation services
Technologically advanced clinical infrastructure and trained personnel ensuring high quality and reliable diagnostic services
High brand recall and commitment to superior quality, driving high individual consumer business share and customer retention
05
Track record of profitability and consistent financial performance
06
Management team with robust industry experience
24
Key Differentiating Factors
Polyclinic
Diversified in terms of revenue from services
132
Chambers1
1,000+
Doctors1
Omnichannel medical consultation services via online and offline modes through diagnostic centres which house the polyclinic chambers
Model of integrated pathology, radiology and medical consultation services offers significant barriers to entry
Comprehensive suite of 2,300+ diagnostic tests1
45%
55%
12%
88%
Pathology
Radiology
Routine
Specialized
Basic / Intermediate
Advanced
Note: 1) as of 31 March 2025
Revenue
51%
45%
4%
Pathology
Radiology
OPDConsultation
Revenue contribution from Pathology, Radiology and OPD Consultation (% of FY25 revenue)
25
Strategies to Drive Future Growth
Strengthen position in core geography
Expand in adjacent geographies of Eastern and North- Eastern India
Supplement organic growth with selective acquisitions
Leverage technology to elevate customer experience
Increase share of medical consultation services at diagnostic centres
Engage in Business- to-Business (“B2B”) and corporate partnerships
01
02
03
04
05
06
26
Targeting Organic and Inorganic Opportunities in Core and Adjacent Markets
Consolidate leading position in the core geography by
Expand in adjacent geographies of Eastern and North-Eastern India
Supplement organic growth with selective acquisitions
Open additional diagnostic centres and increase franchisee partnerships with local entrepreneurs
Enhance the laboratory capacity and test menu by adding latest technologies
Increase home collection services
Identify key locations in Eastern and North-Eastern India
Replicate the (a) ‘hub and spoke’ model to unlock economies of scale (b) polyclinic model to drive higher number of patient footfalls
Build spoke centers around the existing hub centers in Bihar, Guwahati and Meghalaya
Selective acquisitions of and/or strategic partnerships with local diagnostic centres across Eastern and North-Eastern India
Factors while evaluating acquisition targets • Brand recognition • Customer base • Technical capability and resources
Set up more hub centres to form new clusters, and spoke centres in existing clusters
Wider geographic reach will expand the customer base as well as improve the profitability by allowing to better leverage the infrastructure
Leverage technology to elevate customer experience
Increase share of medical consultation services at diagnostic centres
Engage in Business-to-business (“B2B”) and corporate partnerships
Create a convenient one-stop solution through integration of digital technology, artificial intelligence and machine learning
Increase the touch points and engagement with customers through digital and technological initiatives
Set up more polyclinics in the existing diagnostic centres, and increase the number and specialties of doctors associated
Enhance revenue from the B2B segment to further diversify revenue mix and increase customer base & brand penetration
Achieve higher footfalls, tests per patient, and average revenue per patient
Actively seek institutional customers through referrals or internal lead-generation
27
Industry Overview
28
Industry: Poised for High Growth; Shifting Towards Organized Market
Diagnostic market expected to grow at 10-12% CAGR between FY24 & FY28
Organized players gaining market share from standalone labs at a steady rate
36-40%
13- 17%
45-49%
FY201
20- 24%
36-40%
35-39%
FY24E1
Diagnostic chains
Hospital Based
Standalone
Estimated break-up of the Indian diagnostics industry
CAGR 10-12%
1,275-1,375
860-870
FY24E
FY28P
Indian Diagnostic Industry (INR bn)
Pathology
56%
Radiology
44%
Radiology expected to grow at a relatively faster pace
CAGR 9-11%
700-755
480-490
FY24E
FY28P
CAGR 11-13%
570-620
375-385
FY24E
FY28P
Radiology Market (INR bn)
29
Segment wise break-up of diagnostics market (FY24E)
Pathology Market (INR bn)
Source: CRISIL Report Note: 1) For FY20 & FY24E, Multiregional Chains account for 35-40% & 34-38% respectively of the overall Diagnostic Chains; For FY20 & FY24E, Regional Chains account for 60-65% & 62-66% respectively of the overall Diagnostic Chains
Eastern India - An “Underserved” Market with Premium Pricing
Disparity in access to accredited testing services in Eastern(1) India relative to population needs
Region has the lowest number of NABH accredited hospitals
East India(1) market also offers premium pricing for diagnostic tests
2.50
430
1.62
1.60
Average: 1.61
187
227
0.96
North
South
West
East¹
North
South
West
70-80
55-65
80-90
80-90
North
South
West
East & North East1
Average: 179
50
East & North East
1
# NABL labs per mn population (Feb 2024)
# Region wise NABH accredited hospitals
Region-wise average diagnostic test expenditure(2) (INR)
East India(1) has the highest share of population, yet the lowest share of Indian diagnostics market
East India(1) diagnostics market is expected to grow at 10.5-12.5% CAGR between FY24 and FY28
West Bengal diagnostics market is expected to grow at 10.5-12.5% CAGR between FY24 and FY28
INR (bn)
CAGR 10.5-12.5%
260-280
INR (bn)
CAGR 10.5-12.5%
170-180
% share of population in East India, FY24E(1)
% share of East India(1) diagnostics market, FY24E
FY24E
FY28P
Source: CRISIL Report Note: 1) East including Northeast region is defined as: Bihar, Jharkhand, Odisha, West Bengal, Chhattisgarh: Sikkim, Arunachal Pradesh, Assam, Tripura, Mizoram, Nagaland, Manipur, Meghalaya; 2) For non-hospitalization
61-63
FY24E
95-100
FY28P
30
Key Awards & Recognition
2017
Best quality in service delivery(1)
2019
Best customer service in healthcare(1)
2021
Business leader of the year(2)
2021
Awards & certificate of excellence(3)
2022
Outstanding diagnostic chain of eastern India(4)
2023
Certificate of excellence in exemplary trust & commitment towards diagnostic services(5)
Note: 1) Awarded by ABP News; 2) by the World Leadership Congress & Awards; 3) By Zee24 Ghanta; 4) by ABP Ananda; 5) at the Health Conclave 2023 organized by Zee24 Ghanta
31
Thank You
For further information, please contact:
Company :
Suraksha Diagnostic Limited CIN: L85110WB2005PLC102265 Email: investors@surakshanet.com
investors@surakshanet.com
Investor Relations Advisors :
MUFG Intime India Private Limited A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services
Mr. Ashish Tendulkar ashish.tendulkar@in.mpms.mufg.com
Ms. Pooja Swami pooja.swami@in.mpms.mufg.com
Meeting Request Link – Click Here
Click Here